AbCellera Biologics Inc (ABCL)
3.98
-0.03
(-0.75%)
USD |
NASDAQ |
Apr 23, 16:00
3.98
0.00 (0.00%)
After-Hours: 20:00
AbCellera Biologics Revenue (TTM): 38.03M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 38.03M |
| September 30, 2023 | 50.39M |
| June 30, 2023 | 145.18M |
| March 31, 2023 | 181.04M |
| December 31, 2022 | 485.43M |
| September 30, 2022 | 603.21M |
| June 30, 2022 | 507.34M |
| Date | Value |
|---|---|
| March 31, 2022 | 489.06M |
| December 31, 2021 | 375.22M |
| September 30, 2021 | 443.80M |
| June 30, 2021 | 447.65M |
| March 31, 2021 | 431.24M |
| December 31, 2020 | 233.16M |
| September 30, 2020 | 28.45M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
28.45M
Minimum
Sep 2020
603.21M
Maximum
Sep 2022
318.51M
Average
403.23M
Median
Revenue (TTM) Benchmarks
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 175.51M |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.386M |
| InMed Pharmaceuticals Inc | 5.487M |